Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis

NCT01807520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Moderate to Severe Nail Psoriasis

Interventions

BIOLOGICAL: Secukinumab
BIOLOGICAL: Placebo

Sponsor

Novartis Pharmaceuticals